Anocca AB (Anocca), a leading T-cell receptor-engineered T-cell (TCR-T) therapeutics company, and Shinobi Therapeutics (Shinobi), developer of immune-evasive induced pluripotent stem cell (iPSC)-derived CD8 αβT-cell therapies (iPS-T), announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of… Continue reading Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology